NASDAQ:CCXI

Chemocentryx Stock News

etoro logo Buy CCXI
*Your capital is at risk
$10.24
+0.0150 (+0.147%)
At Close: Jun 03, 2026
ChemoCentryx (CCXI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Equities research analysts expect ChemoCentryx Inc (NASDAQ:CCXI) to post sales of $8.90 million for the current quarter, Zacks reports. Five analysts have made estimates for ChemoCentryx’s earnings,
Zacks Investment Research upgraded shares of ChemoCentryx (NASDAQ:CCXI) from a hold rating to a buy rating in a report issued on Tuesday, Zacks.com reports. Zacks Investment Research currently has $58

Biotech Melt-Up

01:00pm, Thursday, 23'rd Apr 2020
A high daily death toll suggests a much more careful and measured reopening of the economy will be possible, not a quick-paced one. The pandemic thrusts the bio
Does ChemoCentryx (CCXI) have what it takes to be a top stock pick for momentum investors? Let's find out.
Does ChemoCentryx (CCXI) have what it takes to be a top stock pick for momentum investors? Let's find out.
Bank of America Corp DE reduced its position in shares of ChemoCentryx Inc (NASDAQ:CCXI) by 51.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs April 20) * Abbott Laboratories (NYSE: ABT) * Acceleron Phar
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs April 20) Abbott Laboratories (NYSE...
Frontier Capital Management Co. LLC cut its position in shares of ChemoCentryx Inc (NASDAQ:CCXI) by 91.5% during the first quarter, according to the company in its most recent disclosure with the Secu
After Merrill Lynch and Oppenheimer gave Ascendis Pharma (NASDAQ: ASND) a Buy rating last month, the company received another Buy, this time from
After Merrill Lynch and Oppenheimer gave Ascendis Pharma (NASDAQ: ASND) a Buy rating last month, the company received another Buy,
ChemoCentryx Inc (NASDAQ:CCXI) was the recipient of a significant growth in short interest in the month of March. As of March 31st, there was short interest totalling 2,570,000 shares, a growth of 15.
ChemoCentryx (NASDAQ:CCXI) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Tuesday, Zacks.com reports. The firm currently has a $52.00 ta
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE